LCFA: Lung Cancer Foundation of America

LCFA: Lung Cancer Foundation of America LCFA’s mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.

Raising public awareness, serving as a resource for patients or anyone seeking answers, hope, and access to updated treatment info. LCFA's mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.

09/09/2026

A lung cancer diagnosis can bring urgent questions.

Take it from Jaymie Knox about the one important question is: "Could comprehensive biomarker testing help guide my treatment plan?"

The period soon after diagnosis is an important time to begin this conversation. Results may help your care team understand the biology of your cancer and consider treatments connected to specific biomarkers.

📌 Save this post and bring the question to your next appointment.

🔗 Learn more: https://bit.ly/3YFvNeH

09/06/2026

Immunotherapy is one of the biggest breakthroughs in lung cancer treatment in decades. It exists because researchers had the funding to chase it.

Dr. Kellie Smith's immunotherapy research — funded through LCFA — is part of that progress. And for patients like Lysa Buonanno, who's lived with lung cancer for five years, that research isn't abstract. It's more time with the people she loves.

🎧 Hear their full conversation: https://bit.ly/4zOO5dD

09/05/2026

"PD-L1" gets mentioned a lot after a lung cancer diagnosis — but what does your score actually mean?

In this episode, Dr. Julie Brahmer (Johns Hopkins) explains it simply: some cancer cells use PD-L1 like a cloaking device to hide from your immune system. Immunotherapy works by interrupting that signal so your body's defenses can do their job.

Your TPS score — from 0 to 100 — helps guide whether immunotherapy alone, immunotherapy plus chemo, or another approach makes the most sense for you.

One key question Dr. Brahmer says every patient should ask: "What is my PD-L1 score?" Bring that question — and a few others — to your next appointment.

🎧 Listen to the full conversation: https://bit.ly/3Rfsw4b

09/04/2026

"One of the first things that excited me was the onslaught of immunotherapies." — Maida Mangiameli, 8-year small cell lung cancer survivor

When Maida was first diagnosed, immunotherapy wasn't even approved yet for small cell lung cancer. In this Hope With Answers℠ conversation with Dr. Jacob Sands of Dana-Farber, they break down how much that's changed:

🔹 Limited-stage disease: The current standard of care is chemotherapy and radiation together, followed by two years of immunotherapy. Dr. Sands explains that adding immunotherapy has improved long-term disease control and survival.
🔹 Even earlier-stage disease: For stage one small cell lung cancer treated with surgery, patients now typically follow with chemotherapy plus immunotherapy — every patient in the trial that established this received both.
🔹 Why now: Dr. Sands points to the pace of scientific progress itself — research and drug development are moving faster than would have seemed possible 20 years ago, bringing more immunotherapy options into the pipeline continuously.

For a disease that saw almost no treatment innovation for decades, this is real, measurable progress. Full conversation: https://bit.ly/4yabMLE

09/03/2026

When Maida Mangiameli was diagnosed with extensive-stage small cell lung cancer, doctors were still treating it with chemo. Immunotherapy wasn't even approved yet. Eight years later, she's celebrating that research now shows that adding two years of immunotherapy after chemo and radiation helps people with limited-stage disease live longer.

Tune in to our brand new Hope With Answers podcast to hear Maida's conversation with lung cancer specialist Dr. Jacob Sands about why small cell lung cancer research is accelerating after decades of slow progress and how immunotherapy is part of it: https://bit.ly/4yabMLE

PD-L1 is a protein the tumor can use like a cloak to hide itself, and your PD-L1 score helps your doctors decide whether...
09/03/2026

PD-L1 is a protein the tumor can use like a cloak to hide itself, and your PD-L1 score helps your doctors decide whether immunotherapy is right for you. It doesn’t tell you how aggressive your cancer is, and it’s not a grade.

Colette Smith, living with lung cancer for more than a decade, sat down with Dr. Julie Brahmer of Johns Hopkins for Hope With Answers to discuss this development in immunotherapy. “We’ve spoken a lot about science and what I hear from all of this is hope.”

Get your free one-page downloadable list that you can bring to your appointment: https://bit.ly/3UyfkJ9

Image: “Negative, low and high PD-L1 expression by immunohistochemistry” by Müller T, Braun M, Dietrich D, Aktekin S, Höft S, Kristiansen G, CC BY 3.0. https://bit.ly/2v1FGI8

09/01/2026

Lung cancer immunotherapy didn't arrive as one big breakthrough — it was built through what Dr. Kellie Smith of Johns Hopkins' Bloomberg-Kimmel Institute for Cancer Immunotherapy calls a series of "hmm moments," starting with the first PD-1 blockade trial back in 2010.

Today, that patient research has grown into a treatment reshaping outcomes: some patients no longer need chemotherapy at all, receiving immunotherapy alone or combined with chemo as their first-line treatment."What we're seeing is there are patients who now don't even need chemotherapy," Dr. Smith notes. "A lot of patients are receiving immunotherapy either alone or in combination with chemotherapy as first-line treatment."
lcfamerica

As Dr. Smith puts it: "Immunotherapy has completely changed the treatment landscape for lung cancer patients."
lcfamerica

The work behind this shift often starts small — Dr. Smith credits her first-ever grant as an independent investigator to LCFA's early career researcher program, funding that helped lead to a clinical trial contributing to FDA approval of immunotherapy for early-stage lung cancer.

🎥 Watch the full conversation: https://bit.ly/4lZbd0P

Palliative care is one of the most misunderstood tools available to lung cancer patients and caregivers.It's not about g...
08/30/2026

Palliative care is one of the most misunderstood tools available to lung cancer patients and caregivers.
It's not about giving up. It's about living as fully as possible, at every stage.
Learn what it actually is, how it's different from hospice, and how you can advocate for your loved one's quality of life →

https://bit.ly/3V2eT6D

It's one of the parts of caregiving that almost never gets talked about — how a lung cancer diagnosis affects intimacy a...
08/29/2026

It's one of the parts of caregiving that almost never gets talked about — how a lung cancer diagnosis affects intimacy and closeness between partners.
You don't have to figure it out alone. Our Hope With Answers episode is an honest, compassionate look at staying connected through treatment and beyond.
Read/watch →

https://bit.ly/3XRetkN

08/28/2026

"No filters. No false reassurance. Just honest conversation about what caregiving really looks like."
In this episode of Hope With Answers, caregiver Gail Fackler and her husband Jim open up about the emotional weight of a lung cancer diagnosis — with guidance from Dr. Allison Applebaum of Memorial Sloan Kettering on protecting your own wellbeing while showing up for someone you love.
🎥 Watch now →

https://bit.ly/4gpIAsQ

Address

PO Box 200989
New Ulm, MN
75320

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+13237414713

Website

Alerts

Be the first to know and let us send you an email when LCFA: Lung Cancer Foundation of America posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to LCFA: Lung Cancer Foundation of America:

Shortcuts

Share